Correlation Engine 2.0
Clear Search sequence regions


  • ABCG2 (1)
  • allopurinol (1)
  • chronic disease (1)
  • diagnosis (1)
  • GLUT9 (1)
  • gout (8)
  • gout lead (1)
  • gout suppressants (2)
  • humans (1)
  • hyperuricaemia (2)
  • IL 1β (1)
  • neutrophil (1)
  • NLRP3 (1)
  • patient (1)
  • phase (1)
  • risk factor (2)
  • serum (2)
  • SLC22A12 (2)
  • SLC2A9 (1)
  • Sizes of these terms reflect their relevance to your search.

    Gout is a common and treatable disease caused by the deposition of monosodium urate crystals in articular and non-articular structures. Increased concentration of serum urate (hyperuricaemia) is the most important risk factor for the development of gout. Serum urate is regulated by urate transporters in the kidney and gut, particularly GLUT9 (SLC2A9), URAT1 (SLC22A12), and ABCG2. Activation of the NLRP3 inflammasome by monosodium urate crystals with release of IL-1β plays a major role in the initiation of the gout flare; aggregated neutrophil extracellular traps are important in the resolution phase. Although presenting as an intermittent flaring condition, gout is a chronic disease. Long-term urate lowering therapy (eg, allopurinol) leads to the dissolution of monosodium urate crystals, ultimately resulting in the prevention of gout flares and tophi and in improved quality of life. Strategies such as nurse-led care are effective in delivering high-quality gout care and lead to major improvements in patient outcomes. Copyright © 2021 Elsevier Ltd. All rights reserved.

    Citation

    Nicola Dalbeth, Anna L Gosling, Angelo Gaffo, Abhishek Abhishek. Gout. Lancet (London, England). 2021 May 15;397(10287):1843-1855

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 33798500

    View Full Text